{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:45:58Z","timestamp":1791215158541,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T00:00:00Z","timestamp":1338249600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1038\/nrgastro.2012.101","type":"journal-article","created":{"date-parts":[[2012,5,29]],"date-time":"2012-05-29T07:48:00Z","timestamp":1338277680000},"page":"406-417","source":"Crossref","is-referenced-by-count":92,"title":["Genetics of IL28B and HCV\u2014response to infection and treatment"],"prefix":"10.1038","volume":"9","author":[{"given":"C. Nelson","family":"Hayes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Aikata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,29]]},"reference":[{"key":"BFnrgastro2012101_CR1","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1126\/science.2523562","volume":"244","author":"QL Choo","year":"1989","unstructured":"Choo, Q. L.  et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359\u2013362 (1989).","journal-title":"Science"},{"key":"BFnrgastro2012101_CR2","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1172\/JCI39133","volume":"119","author":"B Rehermann","year":"2009","unstructured":"Rehermann, B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J. Clin. Invest. 119, 1745\u20131754 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrgastro2012101_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/jlts.2003.50073","volume":"9","author":"GL Davis","year":"2003","unstructured":"Davis, G. L., Albright, J. E., Cook, S. F. & Rosenberg, D. M. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 9, 331\u2013338 (2003).","journal-title":"Liver Transpl."},{"key":"BFnrgastro2012101_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis, S. J.  et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346\u2013355 (2004).","journal-title":"Ann. Intern. Med."},{"key":"BFnrgastro2012101_CR5","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12325-010-0047-0","volume":"27","author":"AJ Fowell","year":"2010","unstructured":"Fowell, A. J. & Nash, K. L. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv. Ther. 27, 512\u2013522 (2010).","journal-title":"Adv. Ther."},{"key":"BFnrgastro2012101_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge, D.  et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399\u2013401 (2009).","journal-title":"Nature"},{"key":"BFnrgastro2012101_CR7","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka, Y.  et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105\u20131109 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2012101_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/ng.447","volume":"41","author":"V Suppiah","year":"2009","unstructured":"Suppiah, V.  et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100\u20131104 (2009).","journal-title":"Nat. Genet."},{"key":"BFnrgastro2012101_CR9","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas, D. L.  et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798\u2013801 (2009).","journal-title":"Nature"},{"key":"BFnrgastro2012101_CR10","doi-asserted-by":"publisher","first-page":"20869","DOI":"10.1074\/jbc.M109.002923","volume":"284","author":"HH Gad","year":"2009","unstructured":"Gad, H. H.  et al. Interferon-\u03bb is functionally an interferon but structurally related to the interleukin-10 family. J. Biol. Chem. 284, 20869\u201320875 (2009).","journal-title":"J. Biol. Chem."},{"key":"BFnrgastro2012101_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/ni875","volume":"4","author":"SV Kotenko","year":"2003","unstructured":"Kotenko, S. V.  et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69\u201377 (2003).","journal-title":"Nat. Immunol."},{"key":"BFnrgastro2012101_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/ni873","volume":"4","author":"P Sheppard","year":"2003","unstructured":"Sheppard, P.  et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63\u201368 (2003).","journal-title":"Nat. Immunol."},{"key":"BFnrgastro2012101_CR13","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0b013e318204ed70","volume":"34","author":"K Yoshimoto","year":"2011","unstructured":"Yoshimoto, K.  et al. Interleukin-28B acts synergistically with cisplatin to suppress the growth of head and neck squamous cell carcinoma. J. Immunother. 34, 139\u2013148 (2011).","journal-title":"J. Immunother."},{"key":"BFnrgastro2012101_CR14","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1038\/mt.2010.118","volume":"18","author":"MP Morrow","year":"2010","unstructured":"Morrow, M. P.  et al. IL-28B\/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol. Ther. 18, 1714\u20131723 (2010).","journal-title":"Mol. Ther."},{"key":"BFnrgastro2012101_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2010.11.019","volume":"55","author":"L Zhang","year":"2011","unstructured":"Zhang, L.  et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J. Hepatol. 55, 289\u2013298 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR16","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1128\/JVI.02438-06","volume":"81","author":"Z Zhou","year":"2007","unstructured":"Zhou, Z.  et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81, 7749\u20137758 (2007).","journal-title":"J. Virol."},{"key":"BFnrgastro2012101_CR17","doi-asserted-by":"publisher","first-page":"11564","DOI":"10.1073\/pnas.0904477106","volume":"106","author":"SJ Thomson","year":"2009","unstructured":"Thomson, S. J.  et al. The role of transposable elements in the regulation of IFN-\u03bb1 gene expression. Proc. Natl Acad. Sci. USA 106, 11564\u201311569 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro2012101_CR18","doi-asserted-by":"publisher","first-page":"e1000017","DOI":"10.1371\/journal.ppat.1000017","volume":"4","author":"C Sommereyns","year":"2008","unstructured":"Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-lambda (IFN-\u03bb) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4, e1000017 (2008).","journal-title":"PLoS Pathog."},{"key":"BFnrgastro2012101_CR19","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1053\/j.gastro.2006.09.052","volume":"131","author":"T Marcello","year":"2006","unstructured":"Marcello, T.  et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887\u20131898 (2006).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR20","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1128\/JVI.02591-09","volume":"84","author":"MB Iversen","year":"2010","unstructured":"Iversen, M. B., Ank, N., Melchjorsen, J. & Paludan, S. R. Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs. J. Virol. 84, 4579\u20134586 (2010).","journal-title":"J. Virol."},{"key":"BFnrgastro2012101_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"DL Thomas","year":"2000","unstructured":"Thomas, D. L.  et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284, 450\u2013456 (2000).","journal-title":"JAMA"},{"key":"BFnrgastro2012101_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJM199904223401602","volume":"340","author":"E Kenny-Walsh","year":"1999","unstructured":"Kenny-Walsh, E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Engl. J. Med. 340, 1228\u20131233 (1999).","journal-title":"N. Engl. J. Med."},{"key":"BFnrgastro2012101_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00535-005-1558-3","volume":"40","author":"M Naito","year":"2005","unstructured":"Naito, M.  et al. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C. J. Gastroenterol. 40, 381\u2013388 (2005).","journal-title":"J. Gastroenterol."},{"key":"BFnrgastro2012101_CR24","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1053\/j.gastro.2009.01.061","volume":"136","author":"H Tsukada","year":"2009","unstructured":"Tsukada, H.  et al. A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology 136, 1796\u20131805 e6 (2009).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S1386-6346(02)00269-3","volume":"25","author":"N Matsuyama","year":"2003","unstructured":"Matsuyama, N.  et al. The dinucleotide microsatellite polymorphism of the IFNAR1 gene promoter correlates with responsiveness of hepatitis C patients to interferon. Hepatol. Res. 25, 221\u2013225 (2003).","journal-title":"Hepatol. Res."},{"key":"BFnrgastro2012101_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/sj.gene.6363984","volume":"4","author":"S Knapp","year":"2003","unstructured":"Knapp, S.  et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4, 411\u2013419 (2003).","journal-title":"Genes Immun."},{"key":"BFnrgastro2012101_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2011.03.006","volume":"55","author":"CM Lange","year":"2011","unstructured":"Lange, C. M. & Zeuzem, S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J. Hepatol. 55, 692\u2013701 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR28","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1053\/j.gastro.2009.12.056","volume":"138","author":"A Rauch","year":"2010","unstructured":"Rauch, A.  et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338\u20131345 e1\u20137 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR29","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1053\/j.gastro.2010.02.009","volume":"138","author":"JJ McCarthy","year":"2010","unstructured":"McCarthy, J. J.  et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 138, 2307\u20132314 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR30","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1053\/j.gastro.2010.07.005","volume":"139","author":"HL Tillmann","year":"2010","unstructured":"Tillmann, H. L.  et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 139, 1586\u20131592 e1 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR31","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/hep.24298","volume":"53","author":"A Ruiz-Extremera","year":"2011","unstructured":"Ruiz-Extremera, A.  et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 53, 1830\u20131838 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1089\/aid.2011.0096","volume":"28","author":"VR Lunge","year":"2011","unstructured":"Lunge, V. R.  et al. IL28B polymorphism associated with spontaneous clearance of hepatitis C infection in a Southern Brazilian HIV type 1 population. AIDS Res. Hum. Retroviruses 28, 215\u2013219 (2011).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"BFnrgastro2012101_CR33","doi-asserted-by":"publisher","first-page":"1320\u2013325 e","DOI":"10.1053\/j.gastro.2011.04.005","volume":"141","author":"S Knapp","year":"2011","unstructured":"Knapp, S.  et al. A polymorphism in IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV infection. Gastroenterology 141, 1320\u2013325 e\u20132 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR34","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/hep.510250342","volume":"25","author":"K Chayama","year":"1997","unstructured":"Chayama, K.  et al. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection. Hepatology 25, 745\u2013749 (1997).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/gut.2010.223495","volume":"60","author":"CN Hayes","year":"2011","unstructured":"Hayes, C. N.  et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 60, 261\u2013267 (2011).","journal-title":"Gut"},{"key":"BFnrgastro2012101_CR36","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1111\/j.1365-2893.2010.01425.x","volume":"18","author":"M Lindh","year":"2011","unstructured":"Lindh, M.  et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon\/ribavirin for chronic hepatitis C genotype 1. J. Viral Hepat. 18, e325\u2013331 (2011).","journal-title":"J. Viral Hepat."},{"key":"BFnrgastro2012101_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1099\/vir.0.029124-0","volume":"92","author":"H Ochi","year":"2011","unstructured":"Ochi, H.  et al. IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations. J. Gen. Virol. 92, 1071\u20131081 (2011).","journal-title":"J. Gen. Virol."},{"key":"BFnrgastro2012101_CR38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1053\/j.gastro.2010.04.013","volume":"139","author":"AJ Thompson","year":"2010","unstructured":"Thompson, A. J.  et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 139, 120\u2013129 e18 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR39","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/hep.23976","volume":"53","author":"ML Yu","year":"2011","unstructured":"Yu, M. L.  et al. Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology 53, 7\u201313 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/hep.24458","volume":"54","author":"A Mangia","year":"2011","unstructured":"Mangia, A.  et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology 54, 772\u2013780 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR41","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jhep.2011.01.050","volume":"55","author":"PY Bochud","year":"2011","unstructured":"Bochud, P. Y.  et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J. Hepatol. 55, 980\u2013988 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR42","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/hep.24154","volume":"53","author":"A Moghaddam","year":"2011","unstructured":"Moghaddam, A.  et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 53, 746\u2013754 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR43","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/infdis\/jir264","volume":"204","author":"J Scott","year":"2011","unstructured":"Scott, J.  et al. IL28B genotype effects during early treatment with peginterferon and ribavirin in difficult-to-treat hepatitis C virus infection. J. Infect. Dis. 204, 419\u2013425 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro2012101_CR44","doi-asserted-by":"publisher","first-page":"e18322","DOI":"10.1371\/journal.pone.0018322","volume":"6","author":"CY Lin","year":"2011","unstructured":"Lin, C. Y.  et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE 6, e18322 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2012101_CR45","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cgh.2010.07.019","volume":"9","author":"AF Stattermayer","year":"2011","unstructured":"Stattermayer, A. F.  et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin. Gastroenterol. Hepatol. 9, 344\u2013350 e2 (2011).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"BFnrgastro2012101_CR46","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1073\/pnas.1100349108","volume":"108","author":"CS Hsu","year":"2011","unstructured":"Hsu, C. S.  et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl Acad. Sci. USA 108, 3719\u20133724 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro2012101_CR47","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/j.gastro.2010.11.039","volume":"140","author":"MT Dill","year":"2011","unstructured":"Dill, M. T.  et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 140, 1021\u20131031 (2011).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR48","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1053\/j.gastro.2010.04.049","volume":"139","author":"M Honda","year":"2010","unstructured":"Honda, M.  et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 139, 499\u2013509 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR49","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","unstructured":"Sarasin-Filipowicz, M.  et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci USA 105, 7034\u20137039 (2008).","journal-title":"Proc. Natl Acad. Sci USA"},{"key":"BFnrgastro2012101_CR50","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jhep.2010.09.019","volume":"54","author":"H Abe","year":"2011","unstructured":"Abe, H.  et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J. Hepatol. 54, 1094\u20131101 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR51","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1002\/jmv.22158","volume":"83","author":"H Abe","year":"2011","unstructured":"Abe, H.  et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J. Med. Virol. 83, 1597\u20131607 (2011).","journal-title":"J. Med. Virol."},{"key":"BFnrgastro2012101_CR52","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1053\/j.gastro.2010.07.055","volume":"139","author":"FM Shebl","year":"2010","unstructured":"Shebl, F. M.  et al. In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with IL28B genotype. Gastroenterology 139, 1422\u20131424 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR53","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/hep.24623","volume":"55","author":"Y Asahina","year":"2011","unstructured":"Asahina, Y.  et al. Association of gene expression involving innate immunity and genetic variation in IL28B with antiviral response. Hepatology 55, 20\u201329 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR54","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jhep.2010.03.022","volume":"53","author":"H Abe","year":"2010","unstructured":"Abe, H.  et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J. Hepatol. 53, 439\u2013443 (2010).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR55","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jhep.2010.07.019","volume":"54","author":"C Fabris","year":"2011","unstructured":"Fabris, C.  et al. IL-28B rs12979860 C\/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J. Hepatol. 54, 716\u2013722 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR56","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s10875-011-9547-1","volume":"31","author":"E Falleti","year":"2011","unstructured":"Falleti, E.  et al. Role of interleukin 28B rs12979860 C\/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J. Clin. Immunol. 31, 891\u2013899 (2011).","journal-title":"J. Clin. Immunol."},{"key":"BFnrgastro2012101_CR57","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1002\/hep.24503","volume":"54","author":"F Marabita","year":"2011","unstructured":"Marabita, F.  et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 54, 1127\u20131134 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR58","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/hep.23592","volume":"51","author":"JH Li","year":"2010","unstructured":"Li, J. H.  et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 51, 1904\u20131911 (2010).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR59","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.jhep.2011.03.015","volume":"55","author":"HL Tillmann","year":"2011","unstructured":"Tillmann, H. L.  et al. Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J. Hepatol. 55, 1195\u20131200 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR60","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1097\/MEG.0b013e328349d0ef","volume":"23","author":"P Halfon","year":"2011","unstructured":"Halfon, P.  et al. A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C genotype 1 virus. Eur. J. Gastroenterol. Hepatol. 23, 931\u2013935 (2011).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2012101_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1440-1746.2011.06834.x","volume":"27","author":"JM Ladero","year":"2011","unstructured":"Ladero, J. M.  et al. Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data. J. Gastroenterol. Hepatol. 27, 279\u2013285 (2011).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnrgastro2012101_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/gm273","volume":"3","author":"KR Smith","year":"2011","unstructured":"Smith, K. R.  et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 3, 57 (2011).","journal-title":"Genome Med."},{"key":"BFnrgastro2012101_CR63","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.gastro.2010.05.079","volume":"139","author":"A Mangia","year":"2010","unstructured":"Mangia, A.  et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 139, 821\u2013827 e1 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR64","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jhep.2011.09.008","volume":"56","author":"T Asselah","year":"2011","unstructured":"Asselah, T.  et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J. Hepatol. 56, 527\u2013532 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR65","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jhep.2010.07.032","volume":"54","author":"T Kawaoka","year":"2011","unstructured":"Kawaoka, T.  et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J. Hepatol. 54, 408\u2013414 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR66","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1093\/infdis\/jir193","volume":"203","author":"M Lindh","year":"2011","unstructured":"Lindh, M.  et al. Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J. Infect. Dis. 203, 1748\u20131752 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro2012101_CR67","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/jmv.22038","volume":"83","author":"N Sakamoto","year":"2011","unstructured":"Sakamoto, N.  et al. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J. Med. Virol. 83, 871\u2013878 (2011).","journal-title":"J. Med. Virol."},{"key":"BFnrgastro2012101_CR68","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jhep.2010.07.041","volume":"54","author":"C Sarrazin","year":"2011","unstructured":"Sarrazin, C.  et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 54, 415\u2013421 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR69","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/hep.23690","volume":"52","author":"N Akuta","year":"2010","unstructured":"Akuta, N.  et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 52, 421\u2013429 (2010).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/infdis\/jir210","volume":"204","author":"K Chayama","year":"2011","unstructured":"Chayama, K.  et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis. 204, 84\u201393 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro2012101_CR71","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/hep.23850","volume":"52","author":"J Grebely","year":"2010","unstructured":"Grebely, J.  et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology 52, 1216\u20131224 (2010).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR72","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/hep.23624","volume":"52","author":"MA Montes-Cano","year":"2010","unstructured":"Montes-Cano, M. A.  et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 52, 33\u201337 (2010).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR73","first-page":"29","volume":"360","author":"Y Aizawa","year":"2011","unstructured":"Aizawa, Y.  et al. Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C. Mol. Cell. Biochem. 360, 29\u201314 (2011).","journal-title":"Mol. Cell. Biochem."},{"key":"BFnrgastro2012101_CR74","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/hep.23912","volume":"52","author":"TJ Urban","year":"2010","unstructured":"Urban, T. J.  et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888\u20131896 (2010).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR75","doi-asserted-by":"publisher","first-page":"e19799","DOI":"10.1371\/journal.pone.0019799","volume":"6","author":"K Onomoto","year":"2011","unstructured":"Onomoto, K.  et al. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS ONE 6, e19799 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2012101_CR76","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/infdis\/jir113","volume":"203","author":"P Barreiro","year":"2011","unstructured":"Barreiro, P.  et al. Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. J. Infect. Dis. 203, 1629\u20131636 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro2012101_CR77","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/ni1243","volume":"6","author":"T Kawai","year":"2005","unstructured":"Kawai, T.  et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981\u2013988 (2005).","journal-title":"Nat. Immunol."},{"key":"BFnrgastro2012101_CR78","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.molcel.2005.08.014","volume":"19","author":"LG Xu","year":"2005","unstructured":"Xu, L. G.  et al. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell. 19, 727\u2013740 (2005).","journal-title":"Mol. Cell."},{"key":"BFnrgastro2012101_CR79","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.cell.2005.08.012","volume":"122","author":"RB Seth","year":"2005","unstructured":"Seth, R. B., Sun, L., Ea, C. K. & Chen, Z. J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122, 669\u2013682 (2005).","journal-title":"Cell"},{"key":"BFnrgastro2012101_CR80","doi-asserted-by":"publisher","first-page":"7034","DOI":"10.1073\/pnas.0707882105","volume":"105","author":"M Sarasin-Filipowicz","year":"2008","unstructured":"Sarasin-Filipowicz, M.  et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc. Natl Acad. Sci. USA 105, 7034\u20137039 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrgastro2012101_CR81","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/hep.24189","volume":"53","author":"Z Makowska","year":"2011","unstructured":"Makowska, Z., Duong, F. H., Trincucci, G., Tough, D. F. & Heim, M. H. Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo. Hepatology 53, 1154\u20131163 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR82","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1002\/hep.23743","volume":"52","author":"AJ Muir","year":"2010","unstructured":"Muir, A. J.  et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52, 822\u2013832 (2010).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR83","doi-asserted-by":"publisher","first-page":"e20904","DOI":"10.1371\/journal.pone.0020904","volume":"6","author":"TR O'Brien","year":"2011","unstructured":"O'Brien, T. R.  et al. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS ONE 6, e20904 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrgastro2012101_CR84","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1478-3231.2011.02449.x","volume":"31","author":"M Romero-Gomez","year":"2011","unstructured":"Romero-Gomez, M., Eslam, M., Ruiz, A. & Maraver, M. Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment. Liver Int. 31, 443\u2013460 (2011).","journal-title":"Liver Int."},{"key":"BFnrgastro2012101_CR85","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.jhep.2010.07.037","volume":"54","author":"M Kurosaki","year":"2011","unstructured":"Kurosaki, M.  et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J. Hepatol. 54, 439\u2013448 (2011).","journal-title":"J. Hepatol."},{"key":"BFnrgastro2012101_CR86","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1093\/infdis\/jir726","volume":"205","author":"H Ochi","year":"2012","unstructured":"Ochi, H.  et al. Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C. J. Infect. Dis. 205, 204\u2013210 (2012).","journal-title":"J. Infect. Dis."},{"key":"BFnrgastro2012101_CR87","doi-asserted-by":"publisher","first-page":"e1001092","DOI":"10.1371\/journal.pmed.1001092","volume":"8","author":"V Suppiah","year":"2011","unstructured":"Suppiah, V.  et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European cohort: a cross-sectional study. PLoS Med. 8, e1001092 (2011).","journal-title":"PLoS Med."},{"key":"BFnrgastro2012101_CR88","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/ajg.2011.82","volume":"106","author":"PM de Rueda","year":"2011","unstructured":"de Rueda, P. M.  et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am. J. Gastroenterol. 106, 1246\u20131254 (2011).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrgastro2012101_CR89","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.1365-2036.2011.04635.x","volume":"33","author":"G Fattovich","year":"2011","unstructured":"Fattovich, G.  et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment. Pharmacol. Ther. 33, 1162\u20131172 (2011).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrgastro2012101_CR90","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1002\/hep.24201","volume":"53","author":"D Bitetto","year":"2011","unstructured":"Bitetto, D.  et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C\/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology 53, 1118\u20131126 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR91","doi-asserted-by":"publisher","unstructured":"Akuta, N.  et al. Amino acid substitution in hcv core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment. Intervirology \n                    http:\/\/dx.doi.org\/10.1159\/000323526\n                    \n                  .","DOI":"10.1159\/000323526"},{"key":"BFnrgastro2012101_CR92","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1053\/j.gastro.2010.07.058","volume":"139","author":"T Fukuhara","year":"2010","unstructured":"Fukuhara, T.  et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 139, 1577\u20131585 e1\u2013e3 (2010).","journal-title":"Gastroenterology"},{"key":"BFnrgastro2012101_CR93","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/hep.24074","volume":"53","author":"MR Charlton","year":"2011","unstructured":"Charlton, M. R.  et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 53, 317\u2013324 (2011).","journal-title":"Hepatology"},{"key":"BFnrgastro2012101_CR94","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1600-6143.2011.03491.x","volume":"11","author":"M Coto-Llerena","year":"2011","unstructured":"Coto-Llerena, M.  et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am. J. Transplant. 11, 1051\u20131057 (2011).","journal-title":"Am. J. Transplant."},{"key":"BFnrgastro2012101_CR95","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1101\/gr.229102","volume":"12","author":"WJ Kent","year":"2002","unstructured":"Kent, W. J.  et al. The human genome browser at UCSC. Genome Res. 12, 996\u20131006 (2002).","journal-title":"Genome Res."},{"key":"BFnrgastro2012101_CR96","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000328327","volume":"55","author":"N Akuta","year":"2011","unstructured":"Akuta, N.  et al. Amino acid substitution in HCV core\/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy. Intervirology 55, 231\u2013241 (2011).","journal-title":"Intervirology"},{"key":"BFnrgastro2012101_CR97","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2893.2008.01012.x","volume":"16","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem, S.  et al. Expert opinion on the treatment of patients with chronic hepatitis C. J. Viral Hepat. 16, 75\u201390 (2009).","journal-title":"J. Viral Hepat."}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.101","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrgastro.2012.101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:44:51Z","timestamp":1684467891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrgastro.2012.101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,29]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["BFnrgastro2012101"],"URL":"https:\/\/doi.org\/10.1038\/nrgastro.2012.101","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,29]]}}}